Clinical Trial Update: Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of combining veltuzumab with fractionated Y-90 epratuzumab radioimmunotherapy in follicular lymphoma; study terminated with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Epratuzumab (epratuzumab)
• Veltuzumab (veltuzumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Follicular Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-06-02